Conclusions
SUBCLINICAL HYPOTHYROIDISM
Our study indicates that vitamin D administration at a dose of 50,000 IU/week for 12 weeks decreases serum TSH and TC levels and elevates irisin levels in women with subclinical hypothyroidism without significantly affecting other lipid profile parameters. Moreover, vitamin D supplementation improved body composition in these patients. Hence, the consumption of vitamin D might be a helpful approach to control subclinical hypothyroidism in women. Nevertheless, more well-designed clinical trials are warranted to confirm these findings and to clarify the vitamin D supplementation effects on both genders of patients.